0000000000288768

AUTHOR

Sacco R

showing 5 related works from this author

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

2011

Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessmen…

OncologySorafenibLiver CirrhosisNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.drug_classPyridinesAntineoplastic AgentsGastroenterologyTyrosine-kinase inhibitorsystemic therapyliver cancerLiver diseaseInternal medicinemedicineHumansPharmacology (medical)treatmentbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDisease Managementhepatocellular carcinomamedicine.diseasehepatocellular carcinoma sorafenb cirrhosisdigestive system diseasesOncologyTolerabilityHepatocellular carcinomasorafenibLiver functionLiver cancerbusinessmanagementmedicine.drugcirrhosi
researchProduct

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

2017

Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follo…

SorafenibMaleNiacinamidemedicine.medical_specialtyStandard of careCarcinoma HepatocellularAntineoplastic AgentsGastroenterologyIntermediate stage03 medical and health sciences0302 clinical medicineHCC; BCLC-B; Intermediate stage; Treatment; HepatologyInternal medicinemedicineHumansChemoembolization TherapeuticHCCPropensity ScoreAgedNeoplasm StagingRetrospective Studiesintermediate stageHepatologytreatmentbusiness.industryPatient SelectionPhenylurea CompoundsLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAStandard of CareHepatologyMiddle AgedSorafenibmedicine.diseaseSurvival AnalysisTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matchingMultivariate Analysis030211 gastroenterology & hepatologyFemaleLiver functionLiver cancerbusinessBCLC-Bmedicine.drug
researchProduct

Body mass index and complications following major gastrointestinal surgery

2018

Aim Previous studies reported conflicting evidence on the effects of obesity on outcomes after gastrointestinal surgery. The aims of this study were to explore the relationship of obesity with major postoperative complications in an international cohort and to present a meta-analysis of all available prospective data.Methods This prospective, multicentre study included adults undergoing both elective and emergency gastrointestinal resection, reversal of stoma or formation of stoma. The primary end-point was 30-day major complications (Clavien-Dindo Grades III-V). A systematic search was undertaken for studies assessing the relationship between obesity and major complications after gastroint…

MaleobesityMultivariate analysisGastrointestinal DiseasesIMPACTSettore MED/18 - CHIRURGIA GENERALEBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complications; Gastroenterologydigestive tractTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineGastrointestinal tractRisk FactorsMedicineProspective StudiesProspective cohort studyBody mass indexBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complications; Aged; Europe; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Obesity; Postoperative Complications; Prospective Studies; Risk Factors; Body Mass IndexGastrointestinal NeoplasmsOUTCOMESPostoperative complications; body mass index; body weight; digestive tract; gastrointestinal tract; obesityGastroenterologyMiddle AgedBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complicationsEurope030220 oncology & carcinogenesisMeta-analysisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortFemale030211 gastroenterology & hepatologyCohort studymedicine.medical_specialtybody mass indexMalignancyNO03 medical and health sciencesPostoperative complicationsbody weightSDG 3 - Good Health and Well-beingHumansDigestive tractObesityAgedbusiness.industrypostoperative complications; obesity; digestive tract; gastrointestinal tract; body mass index; body weightMORTALITYBody weightmedicine.diseaseObesitySettore MED/18SurgeryPostoperative complicationPostoperative Complications Obesity Digestive Tract Gastrointestinal Tract Body Mass Index Body Weight.gastrointestinal tractbusinessBody mass indexColorectal Disease
researchProduct

Carga global, regional y nacional de neurológicas. Desórdenes, 1990-2016: un análisis sistemático para el Global Estudio de la carga de enfermedad 20…

2019

Publisher´s version (útgefin grein).

DánarmeinMaleEpidemiologyDiseasesMalalties cerebralsGlobal Burden of DiseaseDisability Evaluation0302 clinical medicineCase fatality ratePsychologyKonurCause of deathAged 80 and overeducation.field_of_studyIncidenceMenTaugavísindiddc:3. Good healthSálfræðiWorld healthMuerteNeurologyGBD 2016 Neurology CollaboratorsBrain diseasesQuality-Adjusted Life YearsAlzheimer diseaseCarga global de enfermedadesNervous systemmedicine.medical_specialtyGlobal burden of diseasesLífsgæðiArticle03 medical and health sciencesHealth SciencesHumansWomeneducationTrastornos neurológicosVLAGAgedScience & Technology3112 NeurosciencesGlobal Burden of Diseases030104 developmental biologyYears of potential life lostΕπιστήμες ΥγείαςDementiaHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesNeurological disorders030217 neurology & neurosurgerydementiaRC0301 basic medicinePediatricsDánartíðniNutrition and Disease3124 Neurology and psychiatryDisease StudyTaugasjúkdómarRisk FactorsVoeding en ZiekteCause of DeathGlobal healthPrevalenceNeurological disorders; Global Burden of DiseasesCauses of deathPublic healthMortality rateMental DisordersAge FactorsPublic Health Global Health Social Medicine and EpidemiologyMiddle Agedneurologic diseaseDeathLýðheilsaFemaleLife Sciences & BiomedicineQuality of lifeAdultPopulationClinical NeurologySex FactorsmedicineLife ScienceDisability-adjusted life year:Medicine [Science]MortalityPsychiatryDisease burdenNeurology & Neurosurgeryburden of neurological disordersFaraldsfræðibusiness.industryKlinisk medicinCauses de la mort1103 Clinical SciencesFolkhälsovetenskap global hälsa socialmedicin och epidemiologiSocioeconomic FactorsKarlarglobal disease burdenNervous System DiseasesCause of death/trendsbusiness
researchProduct